Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1988 Apr;47(4):328–332. doi: 10.1136/ard.47.4.328

Anti-inflammatory drugs modulate histamine release from mast cells induced by fibrinogen degradation products.

E Wojtecka-Lukasik 1, J Stachurska 1, M Kopeć 1, S Maśliński 1
PMCID: PMC1003515  PMID: 2452608

Abstract

The products resulting from proteolytic degradation of human fibrinogen (FDP) were found to induce the release of histamine from rat peritoneal mast cells. Low molecular weight, dialysable peptides (FDP) showed the highest dose dependent, histamine releasing activity. Histamine release induced by FDP was effectively inhibited by the gold compound auranofin at a concentration of 10(-5)-10(-7) mol/l and also by the non-steroidal anti-inflammatory drugs BW 755c, timegadine, medosan, naproxen, and aspirin at the higher concentration range of 10(-4)-10(-6) mol/l. It is concluded that the release of histamine from mast cells may be modulated to some extent by anti-inflammatory drugs, especially auranofin, BW 755c and timegadine, a functional property which may be beneficial in the management of joint disease.

Full text

PDF
328

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alm P. E. Sodium fluoride evoked histamine release from mast cells. A study of cyclic AMP levels and effects of catecholamines. Agents Actions. 1983 Apr;13(2-3):132–137. doi: 10.1007/BF01967316. [DOI] [PubMed] [Google Scholar]
  2. Andersson R. G., Saldeen K., Saldeen T. A fibrin(ogen) derived pentapeptide induces vasodilation, prostacyclin release and an increase in cyclic AMP. Thromb Res. 1983 May 1;30(3):213–218. doi: 10.1016/0049-3848(83)90074-9. [DOI] [PubMed] [Google Scholar]
  3. Bromley M., Fisher W. D., Woolley D. E. Mast cells at sites of cartilage erosion in the rheumatoid joint. Ann Rheum Dis. 1984 Feb;43(1):76–79. doi: 10.1136/ard.43.1.76. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buczko W., Moniuszko-Jakoniuk J. Influence of fibrinogen degradation products (FDP) on the central nervous system and on the effects of centrally acting drugs. Pharmacology. 1975;13(3):252–259. doi: 10.1159/000136912. [DOI] [PubMed] [Google Scholar]
  5. Buluk K., Malofiejew M. The pharmacological properties of fibrinogen degradation products. Br J Pharmacol. 1969 Jan;35(1):79–89. doi: 10.1111/j.1476-5381.1969.tb07968.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Crisp A. J., Chapman C. M., Kirkham S. E., Schiller A. L., Krane S. M. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum. 1984 Aug;27(8):845–851. doi: 10.1002/art.1780270802. [DOI] [PubMed] [Google Scholar]
  7. Edgington T. S., Curtiss L. K., Plow E. F. A linkage between the hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides. J Immunol. 1985 Jan;134(1):471–477. [PubMed] [Google Scholar]
  8. Eriksson M., Saldeen K., Saldeen T., Strandberg K., Wallin R. Fibrin-derived vasoactive peptides release histamine. Int J Microcirc Clin Exp. 1983;2(4):337–345. [PubMed] [Google Scholar]
  9. Frewin D. B., Cleland L. G., Jonsson J. R., Robertson P. W. Histamine levels in human synovial fluid. J Rheumatol. 1986 Feb;13(1):13–14. [PubMed] [Google Scholar]
  10. Godfrey H. P., Ilardi C., Engber W., Graziano F. M. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum. 1984 Aug;27(8):852–856. doi: 10.1002/art.1780270803. [DOI] [PubMed] [Google Scholar]
  11. Hafström I., Ringertz B., Palmblad J., Malmsten C. Effects of auranofin on leukotriene production and leukotriene stimulated neutrophil function. Agents Actions. 1984 Dec;15(5-6):551–555. doi: 10.1007/BF01966773. [DOI] [PubMed] [Google Scholar]
  12. Hertz F., Chevrier M. M., DeFeudis F. V. Effects of various substances on two types of inflammatory reaction in animals. Gen Pharmacol. 1983;14(4):419–427. doi: 10.1016/0306-3623(83)90025-3. [DOI] [PubMed] [Google Scholar]
  13. Hoffman M., Fuchs H. E., Pizzo S. V. The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and alpha 1-proteinase inhibitor. Thromb Res. 1986 Mar 1;41(5):707–715. doi: 10.1016/0049-3848(86)90368-3. [DOI] [PubMed] [Google Scholar]
  14. Magro A. M. Effect of inhibitors of arachidonic acid metabolism upon IgE and non-IgE-mediated histamine release. Int J Immunopharmacol. 1982;4(1):15–20. doi: 10.1016/0192-0561(82)90004-2. [DOI] [PubMed] [Google Scholar]
  15. Malone D. G., Irani A. M., Schwartz L. B., Barrett K. E., Metcalfe D. D. Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum. 1986 Aug;29(8):956–963. doi: 10.1002/art.1780290803. [DOI] [PubMed] [Google Scholar]
  16. Richardson D. L., Pepper D. S., Kay A. B. Chemotaxis for human monocytes by fibrinogen-derived peptides. Br J Haematol. 1976 Apr;32(4):507–513. doi: 10.1111/j.1365-2141.1976.tb00953.x. [DOI] [PubMed] [Google Scholar]
  17. Roszkowski W., Stachurska J., Gerdin B., Saldeen T., Kopeć M. Peptides cleaved from fibrinogen by plasmin enhance the progression of L-1 sarcoma in BALB/c mice. Eur J Cancer Clin Oncol. 1981 Aug;17(8):889–892. doi: 10.1016/0014-2964(81)90310-8. [DOI] [PubMed] [Google Scholar]
  18. SHORE P. A., BURKHALTER A., COHN V. H., Jr A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther. 1959 Nov;127:182–186. [PubMed] [Google Scholar]
  19. Saldeen T., Ryan J. W., Berryer P. A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin. 1981 Aug 15-Sep 1Thromb Res. 23(4-5):465–470. doi: 10.1016/0049-3848(81)90208-5. [DOI] [PubMed] [Google Scholar]
  20. Stachurska J., Janik M., Kobus M., Luczak M., Szmigielski S., Roszkowski M., Gerdin B., Saldeen T., Kopeć M. Effects of peptides cleaved from human fibrinogen by plasmin on rabbit kidney cells in culture. Thromb Res. 1983 Feb 15;29(4):419–424. doi: 10.1016/0049-3848(83)90245-1. [DOI] [PubMed] [Google Scholar]
  21. Stachurska J., Lopaciuk S., Gerdin B., Saldeen T., Korościk A., Kopeć M. Effects of proteolytic degradation products of human fibrinogen and of human factor VIII on platelet aggregation and vascular permeability. Thromb Res. 1979;15(5-6):663–672. doi: 10.1016/0049-3848(79)90176-2. [DOI] [PubMed] [Google Scholar]
  22. Taylor D. J., Woolley D. E. Evidence for both histamine H1 and H2 receptors on human articular chondrocytes. Ann Rheum Dis. 1987 Jun;46(6):431–435. doi: 10.1136/ard.46.6.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Taylor D. J., Woolley D. E. Histamine H1 receptors on adherent rheumatoid synovial cells in culture: demonstration by radioligand binding and inhibition of histamine-stimulated prostaglandin E production by histamine H1 antagonists. Ann Rheum Dis. 1987 Jun;46(6):425–430. doi: 10.1136/ard.46.6.425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Taylor D. J., Yoffe J. R., Brown D. M., Woolley D. E. Histamine stimulates prostaglandin E production by rheumatoid synovial cells and human articular chondrocytes in culture. Arthritis Rheum. 1986 Feb;29(2):160–165. doi: 10.1002/art.1780290202. [DOI] [PubMed] [Google Scholar]
  25. Watanabe K., Ishida T., Yoshitomi F., Tanaka K. Fibrinogen degradation products influence PGI2 synthesis by cultured porcine aortic endothelial and smooth muscle cells. Atherosclerosis. 1984 May-Jun;51(2-3):151–161. doi: 10.1016/0021-9150(84)90163-1. [DOI] [PubMed] [Google Scholar]
  26. Watanabe K., Tanaka K. Influence of fibrin, fibrinogen and fibrinogen degradation products on cultured endothelial cells. Atherosclerosis. 1983 Jul;48(1):57–70. doi: 10.1016/0021-9150(83)90017-5. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES